Alkermes (ALKS) - 26 Year Stock Split History
Historical stock splits for Alkermes since 1991. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
|Medical||Medical - Biomedical and Genetics||$7.740B||$0.746B|
|Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.|